Healthcare ❯ Clinical Trials

Drug Development

Regulatory Approval Ethical Concerns Precision Medicine AstraZeneca Treatment Efficacy RAS(ON) Inhibitors Phase Trials Global Health Impairment Loss FDA Approval Autoimmune Diseases Orforglipron HIV Treatments Boehringer Ingelheim Antimicrobial Resistance GLP-1 Agonists siRNA Therapy Pipeline Management COPD Treatments Anti-IL-11 Drugs Monoclonal Antibodies Therapeutic Applications Weight Loss Medications

Aristotle Flags Guardant Health as Key Q4 Contributor on Strong Results, Acquisition News

Guardant’s shares have surged over the past year despite a recent pullback.

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

Semnur Goes Public via Denali SPAC, Unveils $100 Million Bitcoin Stock Sale Plan

EU Regulators Back Uplizna as First Treatment for IgG4‑Related Disease